Onconetix, Inc. Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Net
Onconetix, Inc. (ONCO) had Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Net of $19.03 million as of 2023-09-30, per its 10-Q filed 2023-11-17.
Discontinued › Notes › Business Combination, Asset Acquisition, Transaction between Entities under Common Control, and Joint Venture Formation › Business Combination, Recognized Asset Acquired to Liability Assumed, Excess (Less)
us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet · last filed 2023-11-17
- 2023-09-30: Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Net $19.03M.
- 2023-04-19: Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Net $19.03M.
| Period end | Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Net |
|---|---|
| 2023-09-30 | $19.03M 10-Q · filed 2023-11-17 |
| 2023-04-19 | $19.03M 10-Q · filed 2023-10-20 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| HCW Biologics Inc. (HCWB) | United States | $0.004B | -6.15 |
| REVELATION BIOSCIENCES, INC. (REVB) | United States | $0.004B | |
| Aptevo Therapeutics Inc. (APVO) | United States | $0.003B | |
| Sunshine Biopharma Inc. (SBFM) | $0.003B | ||
| 60 DEGREES PHARMACEUTICALS, INC. (SXTP) | United States | $0.004B | -0.59 |
| Alaunos Therapeutics, Inc. (TCRT) | United States | $0.003B | -1.44 |
| Genprex, Inc. (GNPX) | United States | $0.003B | -0.02 |
| Silo Pharma, Inc. (SILO) | United States | $0.003B | -1.57 |
| Lakewood-Amedex Biotherapeutics Inc. (LABT) | United States | $0.004B | |
| Cadrenal Therapeutics, Inc. (CVKD) | United States | $0.004B | -0.90 |